Cite
Chiocca EA, Gelb AB, Chen CC, et al. Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial. Neuro Oncol. 2021;doi: 10.1093/neuonc/noab271.
Chiocca, E. A., Gelb, A. B., Chen, C. C., Rao, G., Reardon, D. A., Wen, P. Y., Bi, W. L., Peruzzi, P., Amidei, C., Triggs, D., Seften, L., Park, G., Grant, J., Truman, K., Buck, J. Y., Hadar, N., Demars, N., Miao, J., Estupinan, T., Loewy, J., Chadha, K., Tringali, J., Cooper, L., & Lukas, R. V. (2021). Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial. Neuro-oncology, . https://doi.org/10.1093/neuonc/noab271
Chiocca, E Antonio, et al. "Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial." Neuro-oncology vol. (2021). doi: https://doi.org/10.1093/neuonc/noab271
Chiocca EA, Gelb AB, Chen CC, Rao G, Reardon DA, Wen PY, Bi WL, Peruzzi P, Amidei C, Triggs D, Seften L, Park G, Grant J, Truman K, Buck JY, Hadar N, Demars N, Miao J, Estupinan T, Loewy J, Chadha K, Tringali J, Cooper L, Lukas RV. Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial. Neuro Oncol. 2021 Nov 26; doi: 10.1093/neuonc/noab271. Epub 2021 Nov 26. PMID: 34850166.
Copy
Download .nbib